238 related articles for article (PubMed ID: 18466070)
1. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.
Fuchs RK; Phipps RJ; Burr DB
J Bone Miner Res; 2008 Oct; 23(10):1689-97. PubMed ID: 18466070
[TBL] [Abstract][Full Text] [Related]
2. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
Allen MR; Turek JJ; Phipps RJ; Burr DB
Bone; 2011 Jul; 49(1):128-32. PubMed ID: 20637914
[TBL] [Abstract][Full Text] [Related]
3. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Frost ML; Siddique M; Blake GM; Moore AE; Marsden PK; Schleyer PJ; Eastell R; Fogelman I
Osteoporos Int; 2012 Aug; 23(8):2107-16. PubMed ID: 21983795
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.
Yano T; Yamada M; Inoue D
Calcif Tissue Int; 2017 Jul; 101(1):102-110. PubMed ID: 28337514
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
Exp Anim; 2006 Jul; 55(4):333-42. PubMed ID: 16880680
[TBL] [Abstract][Full Text] [Related]
7. Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
Exp Anim; 2006 Oct; 55(5):457-66. PubMed ID: 17090962
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.
Iwamoto J; Seki A; Takeda T; Yamada H; Sato Y; Yeh JK
Chin J Physiol; 2008 Jun; 51(3):121-8. PubMed ID: 18935906
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats.
Fisher JE; Scott K; Wei N; Zhao JZ; Cusick T; Tijerina M; Karanam B; Duong L; Glantschnig H
Bone; 2012 Jun; 50(6):1332-42. PubMed ID: 22445539
[TBL] [Abstract][Full Text] [Related]
10. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Oct; 52(5):307-15. PubMed ID: 17190100
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Shen CL; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):21-7. PubMed ID: 16637226
[TBL] [Abstract][Full Text] [Related]
13. Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Mosekilde L; Thomsen JS; Mackey MS; Phipps RJ
Bone; 2000 Nov; 27(5):639-45. PubMed ID: 11062350
[TBL] [Abstract][Full Text] [Related]
14. Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Dec; 52(6):393-401. PubMed ID: 17330501
[TBL] [Abstract][Full Text] [Related]
15. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
[TBL] [Abstract][Full Text] [Related]
16. Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats.
Li QN; Liang NC; Huang LF; Wu T; Hu B; Mo LE
J Bone Miner Metab; 1999; 17(1):18-22. PubMed ID: 10084397
[TBL] [Abstract][Full Text] [Related]
17. Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents.
Shahnazari M; Yao W; Wang B; Panganiban B; Ritchie RO; Hagar Y; Lane NE
J Bone Miner Res; 2011 Mar; 26(3):569-81. PubMed ID: 20839286
[TBL] [Abstract][Full Text] [Related]
18. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
Allen MR; Iwata K; Phipps R; Burr DB
Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
[TBL] [Abstract][Full Text] [Related]
19. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Tang SY; Allen MR; Phipps R; Burr DB; Vashishth D
Osteoporos Int; 2009 Jun; 20(6):887-94. PubMed ID: 18850239
[TBL] [Abstract][Full Text] [Related]
20. Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.
Yano T; Yamada M; Konda T; Shiozaki M; Inoue D
J Bone Miner Metab; 2014 Nov; 32(6):653-9. PubMed ID: 24357144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
